The UnConference is the annual event to debate the future of healthcare solutions, to raise awareness, perspectives and insight on the sector’s needs and opportunities, and the best way to tackle them. This year the topic of the debate is the advanced therapies. 

Advanced therapies

Advanced therapy medicinal products (ATMPs) offer ground-breaking therapeutic possibilities such as the treatment of previously incurable diseases or conditions. Due to the increase in the burden of chronic diseases, research and development of new therapies nowadays plays an important role in the pharmaceutical and biotech industry. Classic treatments have a significant effect on part of the population, but unfortunately not for every patient, this is one of the main reasons for further development of reliable, verified, and personalized medicines.

To drive the previous aim improved frameworks and value chains need the implementation of an ATMP common strategy. An endeavour that must be undertaken altogether by public and private entities, to avoid a shortage of development and manufacturing that will drive inequalities in the health level of our population. Leverages to achieve it should translate scientific progress into available medical products, promotion of investment and funding, and better competitiveness of our companies with improved market access and regulatory pathway.

The above-mentioned is crucial to increase the opportunity for patients to be treated with novel therapies and ensure technological sovereignty and supply.

PROGRAMME 
(download the full programme)

. Welcome, Institutional Opening and Round Table (9h to 10.30h)

• What infrastructures do we need to be pioneers in advanced therapies? 

. Parallel sessions: challenges to address (11h to 12.30h)

• Challenge I. What are the latest technological trends, innovations, and challenges in advanced therapies?
• Challenge II. What are investors looking for in the field of advanced therapies?
• Challenge III. How to improve market access and regulatory barriers for solutions in advanced therapies?

. Parallel sessions conclusions

. Advanced Therapies Hub: The Catalan Strategy

. Networking cocktail 

Speakers

• Àngel Font, Corporative Director of CaixaResearch Institute
• Andreu Mas-Colell, President, Banc de Sang i Teixits
• Javier García Castro, Head of Cellular Biotechnology Unit, Instituto de Salud Carlos III
• Sol Ruiz, Head of the Advanced Therapies Division, AEMPS
• Toni Andreu, Scientific Director, EATRIS
• Roser Fernández, General Director, La Unió Catalana d'Hospitals
• Núria Montserrat, Group Leader, IBEC, and ICREA Research Professor
• José Antonio Gasquet, Director Oncology Hemathology, Amgen
• Marc Güell, Cofounder and CSO, Integra Therapeutics
• Miguel Chillón, Head of the Research Lab on Gene Therapy for Degenerative Diseases (VHIR-UAB) and Co-Chair  of the Advanced Therapies Medicinal Products Platform, EATRIS
• Luis Pareras, Founder and Managing Partner, Invivo Ventures
• Jose Mesa, Partner, Columbus Venture Partners
• Sara Secall, General Partner, Inveready
• Silvia Ondategui, Partner, Life Sciences Commercial Access Strategy
• Lídia Cánovas, General Manager Regulatory Affairs, Asphalion
• Antoni Vallano, Coordinador of the Pharmacotherapy Harmonisation Programme, Servei Català de la Salut
• Joaquim Delgadillo, Director of Strategic Planning and Advanced Therapies, Banc de Sang i Teixits
• Esteve Trias, Executive Medical Director, Leitat, and Technical Director of the Advanced Therapies Unit, Hospital Clínic Barcelona
• Robert Fabregat, CEO Biocat
• Laia Arnal, Directora General de Transferència i Societat del Coneixement, Generalitat de Catalunya
• Lluís Juncà, Director General d'Innovació, Economia Digital i Emprenedoria, Generalitat de Catalunya
• Aleix Cubells,  Director General de Fons Europeus, Generalitat de Catalunya

Moderators

• Joan Puig de Dou, CEO, Kymos; President, CataloniaBio & HealthTech
• Christian de Angelis, Planta Doce
• Gabriel Trindade, Expansión
• Rosa Salvador, La Vanguardia
• Isabel Amat, Global Head of Innovation and Pipeline Management, Reig Jofre; board member, CataloniaBio & HealthTech

Download the full programme here.

The Unconference is possible thanks to the support of our Gold Sponsor Kymos.

For: C-level management from startups, SMEs and corporations of all disciplines (pharma, medtech, biotech, digital health and services ), as well as knowledge generators (hospitals, R+D centers and universities)

Language: Catalan and Spanish (depending on speakers and attendance)

Registration:

• General: 150€ (VAT not included)
• CataloniaBio & HealthTech members: 80€ (VAT not included)

IMPORTANT! When registering you must select the parallel session in which you will participate.

About the UnConference 2023:

• Report: "CataloniaBio & HealthTech leads a day of debate focused on advanced therapies and their ability to improve quality of life"
• Photo gallery